Executive leadership at Protagenic Therapeutics, Inc.\new.
Board of directors at Protagenic Therapeutics, Inc.\new.
Research analysts covering Protagenic Therapeutics, Inc.\new.
Recent press releases and 8-K filings for PTIX.
Protagenic Therapeutics, Inc. to Begin OTC Trading Following Nasdaq Delisting
PTIX
Delisting/Listing Issues
- Protagenic Therapeutics, Inc. (PTIX) common stock and warrants are expected to begin trading on the over-the-counter market starting January 5, 2026.
- This transition follows a delisting from Nasdaq, with trading ceasing on January 2, 2026.
- The delisting was a result of the company's failure to satisfy Nasdaq's continued listing requirements, specifically Nasdaq Listing Rule 5550(b)(1) (minimum stockholders’ equity) and Nasdaq Listing Rule 5250(c)(1) (timely filing of periodic reports).
- The company has withdrawn its request for a hearing, making Nasdaq's delisting determination final.
- Protagenic Therapeutics, Inc. intends to evaluate steps to regain compliance with Nasdaq listing requirements and seek relisting, and will continue to file periodic and current reports with the SEC.
Jan 5, 2026, 12:45 PM
Protagenic Therapeutics Faces Nasdaq Delisting Over Compliance Issues
PTIX
Delisting/Listing Issues
Profit Warning
New Projects/Investments
- Protagenic Therapeutics received a Nasdaq notification for non-compliance due to insufficient stockholders' equity and a delayed Q3 2025 quarterly report filing, resulting in a delisting decision that the company plans to appeal.
- The company reported a net loss of over $869,000 and a loss from operations of over $1.1 million in Q3 2025, with no revenue and significantly increased operating expenses compared to the prior year.
- Despite acquiring five new preclinical drug candidate assets to expand its pipeline, Protagenic's stock is rated as 'Underperform' by TipRanks' AI Analyst due to weak market momentum, persistent losses, and an unattractive valuation.
Nov 26, 2025, 11:34 PM
Protagenic Therapeutics Receives Nasdaq Delisting Notice
PTIX
Delisting/Listing Issues
Profit Warning
- Protagenic Therapeutics, Inc. (PTIX) received a notification on November 20, 2025, from the Nasdaq Listing Qualifications Staff indicating non-compliance with listing rules.
- The non-compliance is due to not meeting the minimum $2.5 million stockholders' equity requirement as of June 30, 2025, and the delayed filing of its Form 10-Q for the quarter ended September 30, 2025.
- As a result of these deficiencies and a mandatory panel monitoring period, Nasdaq Staff issued a determination to delist the Company's securities.
- PTIX plans to request a hearing before a Nasdaq Hearings Panel to appeal the delisting determination, which will automatically stay any suspension for 15 calendar days.
Nov 26, 2025, 9:18 PM
Ask Fintool AI Agent
Get instant answers from SEC filings, earnings calls & more